{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:33:16Z","timestamp":1793845996398,"version":"4.6.1"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Slaight Family Center for Youth in Transition","award":["Seed funding Award"],"award-info":[{"award-number":["Seed funding Award"]}]},{"name":"Slaight Family Center for Youth in Transition","award":["Seed funding Award"],"award-info":[{"award-number":["Seed funding Award"]}]},{"name":"Slaight Family Center for Youth in Transition","award":["Seed funding Award"],"award-info":[{"award-number":["Seed funding Award"]}]},{"name":"Slaight Family Center for Youth in Transition","award":["Seed funding Award"],"award-info":[{"award-number":["Seed funding Award"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Psychotic disorders have long been considered neurodevelopmental disorders where excessive synaptic pruning and cortical volume loss are central to disease pathology. We conducted a systematic review of the literature to identify neuroimaging studies specifically examining synaptic density across the psychosis spectrum.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>PRISMA guidelines on reporting were followed. We systematically searched MEDLINE, Embase, APA PsycINFO, Web of Science and The Cochrane Library from inception to December 8, 2023, and included all original peer-reviewed articles or completed clinical neuroimaging studies of any modality measuring synaptic density in participants with a diagnosis of psychosis spectrum disorder as well as individuals with psychosis-risk states. The NIH quality assessment tool for observational cohort and cross-sectional studies was used for the risk of bias assessment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Five studies (k\u2009=\u20095) met inclusion criteria, comprising <jats:italic>n<\/jats:italic>\u2009=\u2009128 adults (psychotic disorder; <jats:italic>n<\/jats:italic>\u2009=\u200961 and healthy volunteers; <jats:italic>n<\/jats:italic>\u2009=\u200967 and specifically measuring synaptic density via positron emission tomography (PET) imaging of the synaptic vesicle glycoprotein 2\u00a0A (SV2A). Three studies were included in our primary meta-analysis sharing the same outcome measure of SV2A binding, volume of distribution (V<jats:sub>T<\/jats:sub>). Regional SV2A V<jats:sub>T<\/jats:sub> was reduced in psychotic disorder participants in comparison to healthy volunteers, including the occipital lobe (Mean Difference (MD)= -2.17; 95% CI: -3.36 to -0.98; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001 ), temporal lobe (MD: -2.03; 95% CI: -3.19 to -0.88; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001 ), parietal lobe (MD:-1.61; 95% CI: -2.85 to -0.37; <jats:italic>P<\/jats:italic>\u2009=\u20090.01), anterior cingulate cortex (MD= -1.47; 95% CI: -2.45 to -0.49; <jats:italic>P<\/jats:italic>\u2009=\u20090.003), frontal cortex (MD: -1.16; 95% CI: -2.18 to -0.15; <jats:italic>P<\/jats:italic>\u2009=\u20090.02), amygdala (MD: -1.36; 95% CI: -2.20 to -0.52, <jats:italic>p<\/jats:italic>\u2009=\u20090.002), thalamus (MD:-1.46; 95% CI:-2.46 to -0.46, <jats:italic>p<\/jats:italic>\u2009=\u20090.004) and hippocampus (MD= -0.96; 95% CI: -1.59 to -0.33; <jats:italic>P<\/jats:italic>\u2009=\u20090.003).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Preliminary studies provide in vivo evidence for reduced synaptic density in psychotic disorders. However, replication of findings in larger samples is required prior to definitive conclusions being drawn.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>PROSPERO<\/jats:title>\n                <jats:p>CRD42022359018.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-024-05788-y","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T14:03:21Z","timestamp":1718805801000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A systematic review and meta-analysis of neuroimaging studies examining synaptic density in individuals with psychotic spectrum disorders"],"prefix":"10.1186","volume":"24","author":[{"given":"Muhammad Omair","family":"Husain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usman","family":"Arshad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie H.","family":"Ameis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giselle","family":"Mirfallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christin","family":"Schifani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri","family":"Rodak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madina","family":"Aiken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mudassar","family":"Shafique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristotle","family":"Voineskos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Ishrat","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Foussias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,19]]},"reference":[{"issue":"9995","key":"5788_CR1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S0140-6736(15)60692-4","volume":"386","author":"J \u00c4rnl\u00f6v","year":"2015","unstructured":"\u00c4rnl\u00f6v J, Larsson A. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990\u20132013: a systematic analysis for the global burden of Disease Study 2013. Lancet. 2015;386(9995):743\u2013800.","journal-title":"Lancet"},{"issue":"2","key":"5788_CR2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/schbul\/22.2.327","volume":"22","author":"TH McGlashan","year":"1996","unstructured":"McGlashan TH. Early detection and intervention in schizophrenia: research. Schizophr Bull. 1996;22(2):327\u201345.","journal-title":"Schizophr Bull"},{"key":"5788_CR3","doi-asserted-by":"publisher","first-page":"641319","DOI":"10.3389\/fpsyt.2021.641319","volume":"12","author":"BN Cuthbert","year":"2021","unstructured":"Cuthbert BN, Morris SE. Evolving concepts of the Schizophrenia Spectrum: A Research Domain Criteria Perspective. Front Psychiatry. 2021;12:641319.","journal-title":"Front Psychiatry"},{"key":"5788_CR4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12888-015-0562-2","volume":"15","author":"KR Laurens","year":"2015","unstructured":"Laurens KR, et al. Common or distinct pathways to psychosis? A systematic review of evidence from prospective studies for developmental risk factors and antecedents of the schizophrenia spectrum disorders and affective psychoses. BMC Psychiatry. 2015;15:205.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"5788_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41583-022-00662-w","volume":"24","author":"J Rogers","year":"2023","unstructured":"Rogers J. A shared pathway connects schizophrenia and bipolar disorder. Nat Rev Neurosci. 2023;24(1):2.","journal-title":"Nat Rev Neurosci"},{"issue":"10","key":"5788_CR6","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1017\/S0033291712003091","volume":"43","author":"HL Fisher","year":"2013","unstructured":"Fisher HL, et al. Specificity of childhood psychotic symptoms for predicting schizophrenia by 38 years of age: a birth cohort study. Psychol Med. 2013;43(10):2077\u201386.","journal-title":"Psychol Med"},{"issue":"4","key":"5788_CR7","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1093\/schbul\/16.4.567","volume":"16","author":"I Feinberg","year":"1990","unstructured":"Feinberg I. Cortical pruning and the development of schizophrenia. Schizophr Bull. 1990;16(4):567\u201370.","journal-title":"Schizophr Bull"},{"issue":"1","key":"5788_CR8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/wps.20725","volume":"19","author":"M Keshavan","year":"2020","unstructured":"Keshavan M, Lizano P, Prasad K. The synaptic pruning hypothesis of schizophrenia: promises and challenges. World Psychiatry. 2020;19(1):110\u20131.","journal-title":"World Psychiatry"},{"issue":"3","key":"5788_CR9","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1017\/S0033291717001970","volume":"48","author":"J Mollon","year":"2018","unstructured":"Mollon J, Reichenberg A. Cognitive development prior to onset of psychosis. Psychol Med. 2018;48(3):392\u2013403.","journal-title":"Psychol Med"},{"issue":"1","key":"5788_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41386-022-01426-x","volume":"48","author":"OD Howes","year":"2023","unstructured":"Howes OD, et al. Neuroimaging in schizophrenia: an overview of findings and their implications for synaptic changes. Neuropsychopharmacology. 2023;48(1):151\u201367.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"5788_CR11","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41386-021-01099-y","volume":"47","author":"I Esterlis","year":"2022","unstructured":"Esterlis I, Holmes S. First in vivo evaluations of synaptic density alterations in the brain. Neuropsychopharmacology. 2022;47(1):381\u20132.","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"5788_CR12","doi-asserted-by":"publisher","first-page":"e1004347","DOI":"10.1371\/journal.pcbi.1004347","volume":"11","author":"S Navlakha","year":"2015","unstructured":"Navlakha S, Barth AL, Bar-Joseph Z. Decreasing-rate Pruning optimizes the construction of efficient and robust distributed networks. PLoS Comput Biol. 2015;11(7):e1004347.","journal-title":"PLoS Comput Biol"},{"issue":"2","key":"5788_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0006-8993(79)90349-4","volume":"163","author":"PR Huttenlocher","year":"1979","unstructured":"Huttenlocher PR. Synaptic density in human frontal cortex - developmental changes and effects of aging. Brain Res. 1979;163(2):195\u2013205.","journal-title":"Brain Res"},{"key":"5788_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/neuro.02.008.2009","volume":"2","author":"CR Tessier","year":"2009","unstructured":"Tessier CR, Broadie K. Activity-dependent modulation of neural circuit synaptic connectivity. Front Mol Neurosci. 2009;2:8.","journal-title":"Front Mol Neurosci"},{"issue":"3","key":"5788_CR15","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41593-018-0334-7","volume":"22","author":"CM Sellgren","year":"2019","unstructured":"Sellgren CM, et al. Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning. Nat Neurosci. 2019;22(3):374\u201385.","journal-title":"Nat Neurosci"},{"issue":"4","key":"5788_CR16","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrn.2018.16","volume":"19","author":"MP Forrest","year":"2018","unstructured":"Forrest MP, Parnell E, Penzes P. Dendritic structural plasticity and neuropsychiatric disease. Nat Rev Neurosci. 2018;19(4):215\u201334.","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"5788_CR17","first-page":"374","volume":"46","author":"A van Berdenis","year":"2020","unstructured":"van Berdenis A, et al. Synapse Pathology in Schizophrenia: a Meta-analysis of postsynaptic elements in Postmortem Brain studies. Schizophr Bull. 2020;46(2):374\u201386.","journal-title":"Schizophr Bull"},{"issue":"12","key":"5788_CR18","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/BF02284844","volume":"25","author":"ME Calhoun","year":"1996","unstructured":"Calhoun ME, et al. Comparative evaluation of synaptophysin-based methods for quantification of synapses. J Neurocytol. 1996;25(12):821\u20138.","journal-title":"J Neurocytol"},{"key":"5788_CR19","doi-asserted-by":"publisher","first-page":"796129","DOI":"10.3389\/fnins.2022.796129","volume":"16","author":"ME Serrano","year":"2022","unstructured":"Serrano ME, et al. Imaging synaptic density: the Next Holy Grail of Neuroscience? Front Neurosci. 2022;16:796129.","journal-title":"Front Neurosci"},{"issue":"4","key":"5788_CR20","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41380-018-0041-5","volume":"24","author":"EF Osimo","year":"2019","unstructured":"Osimo EF, et al. Synaptic loss in schizophrenia: a meta-analysis and systematic review of synaptic protein and mRNA measures. Mol Psychiatry. 2019;24(4):549\u201361.","journal-title":"Mol Psychiatry"},{"issue":"2","key":"5788_CR21","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/0306-4522(94)00586-T","volume":"66","author":"SL Eastwood","year":"1995","unstructured":"Eastwood SL, Burnet PW, Harrison PJ. Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia. Neuroscience. 1995;66(2):309\u201319.","journal-title":"Neuroscience"},{"issue":"21","key":"5788_CR22","doi-asserted-by":"publisher","first-page":"8174","DOI":"10.1073\/pnas.0402680101","volume":"101","author":"N Gogtay","year":"2004","unstructured":"Gogtay N, et al. Dynamic mapping of human cortical development during childhood through early adulthood. Proc Natl Acad Sci U S A. 2004;101(21):8174\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"5788_CR23","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1038\/s41380-020-0679-7","volume":"25","author":"C Andreou","year":"2020","unstructured":"Andreou C, Borgwardt S. Structural and functional imaging markers for susceptibility to psychosis. Mol Psychiatry. 2020;25(11):2773\u201385.","journal-title":"Mol Psychiatry"},{"issue":"2","key":"5788_CR24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.biopsych.2014.05.023","volume":"77","author":"TD Cannon","year":"2015","unstructured":"Cannon TD, et al. Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk. Biol Psychiatry. 2015;77(2):147\u201357.","journal-title":"Biol Psychiatry"},{"issue":"7510","key":"5788_CR25","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nature13595","volume":"511","author":"Schizophrenia Working Group of the Psychiatric Genomics","year":"2014","unstructured":"Schizophrenia Working Group of the Psychiatric Genomics. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511(7510):421\u20137.","journal-title":"Nature"},{"issue":"7589","key":"5788_CR26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nature16549","volume":"530","author":"A Sekar","year":"2016","unstructured":"Sekar A, et al. Schizophrenia risk from complex variation of complement component 4. Nature. 2016;530(7589):177\u201383.","journal-title":"Nature"},{"issue":"2","key":"5788_CR27","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ajhg.2019.06.012","volume":"105","author":"M Lam","year":"2019","unstructured":"Lam M, et al. Pleiotropic Meta-analysis of Cognition, Education, and Schizophrenia differentiates roles of early neurodevelopmental and adult synaptic pathways. Am J Hum Genet. 2019;105(2):334\u201350.","journal-title":"Am J Hum Genet"},{"issue":"3","key":"5788_CR28","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41588-019-0344-8","volume":"51","author":"J Grove","year":"2019","unstructured":"Grove J, et al. Identification of common genetic risk variants for autism spectrum disorder. Nat Genet. 2019;51(3):431\u201344.","journal-title":"Nat Genet"},{"key":"5788_CR29","doi-asserted-by":"crossref","unstructured":"Radhakrishnan R et al. In vivo evidence of lower synaptic vesicle density in schizophrenia. Mol Psychiatry, 2021.","DOI":"10.1038\/s41380-021-01184-0"},{"issue":"9","key":"5788_CR30","doi-asserted-by":"publisher","first-page":"5223","DOI":"10.1523\/JNEUROSCI.14-09-05223.1994","volume":"14","author":"SM Bajjalieh","year":"1994","unstructured":"Bajjalieh SM, et al. Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J Neurosci. 1994;14(9):5223\u201335.","journal-title":"J Neurosci"},{"key":"5788_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ddtec.2017.11.003","volume":"25","author":"J Mercier","year":"2017","unstructured":"Mercier J, Provins L, Valade A. Discovery and development of SV2A PET tracers: potential for imaging synaptic density and clinical applications. Drug Discov Today Technol. 2017;25:45\u201352.","journal-title":"Drug Discov Today Technol"},{"issue":"348","key":"5788_CR32","doi-asserted-by":"publisher","first-page":"348ra96","DOI":"10.1126\/scitranslmed.aaf6667","volume":"8","author":"SJ Finnema","year":"2016","unstructured":"Finnema SJ, et al. Imaging synaptic density in the living human brain. Sci Transl Med. 2016;8(348):348ra96.","journal-title":"Sci Transl Med"},{"issue":"2\u20133","key":"5788_CR33","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.schres.2012.08.027","volume":"141","author":"M Mattheisen","year":"2012","unstructured":"Mattheisen M, et al. Genetic variation at the synaptic vesicle gene SV2A is associated with schizophrenia. Schizophr Res. 2012;141(2\u20133):262\u20135.","journal-title":"Schizophr Res"},{"key":"5788_CR34","doi-asserted-by":"publisher","first-page":"113203","DOI":"10.1016\/j.bbr.2021.113203","volume":"405","author":"EF Halff","year":"2021","unstructured":"Halff EF, et al. Effects of chronic exposure to haloperidol, olanzapine or lithium on SV2A and NLGN synaptic puncta in the rat frontal cortex. Behav Brain Res. 2021;405:113203.","journal-title":"Behav Brain Res"},{"issue":"4","key":"5788_CR35","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1038\/s41380-022-01465-2","volume":"27","author":"SE Holmes","year":"2022","unstructured":"Holmes SE, et al. Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. Mol Psychiatry. 2022;27(4):2273\u201381.","journal-title":"Mol Psychiatry"},{"issue":"2 Pt 2","key":"5788_CR36","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3109\/15622970902874932","volume":"11","author":"U Schmitt","year":"2010","unstructured":"Schmitt U, et al. The effects of GABA transporter inhibition on synaptophysin and synaptotagmin expression in diazepam tolerance. World J Biol Psychiatry. 2010;11(2 Pt 2):439\u201346.","journal-title":"World J Biol Psychiatry"},{"issue":"1","key":"5788_CR37","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41467-019-09562-7","volume":"10","author":"SE Holmes","year":"2019","unstructured":"Holmes SE, et al. Lower synaptic density is associated with depression severity and network alterations. Nat Commun. 2019;10(1):1529.","journal-title":"Nat Commun"},{"issue":"3","key":"5788_CR38","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s11307-018-1260-5","volume":"21","author":"CC Constantinescu","year":"2019","unstructured":"Constantinescu CC, et al. Development and in vivo preclinical imaging of Fluorine-18-Labeled synaptic vesicle protein 2A (SV2A) PET Tracers. Mol Imaging Biol. 2019;21(3):509\u201318.","journal-title":"Mol Imaging Biol"},{"issue":"3","key":"5788_CR39","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1021\/acschemneuro.8b00526","volume":"10","author":"S Li","year":"2019","unstructured":"Li S, et al. Synthesis and in vivo evaluation of a novel PET Radiotracer for imaging of synaptic vesicle glycoprotein 2A (SV2A) in Nonhuman Primates. ACS Chem Neurosci. 2019;10(3):1544\u201354.","journal-title":"ACS Chem Neurosci"},{"issue":"5","key":"5788_CR40","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2967\/jnumed.115.168179","volume":"57","author":"NB Nabulsi","year":"2016","unstructured":"Nabulsi NB, et al. Synthesis and preclinical evaluation of 11\u00a0C-UCB-J as a PET Tracer for Imaging the synaptic vesicle glycoprotein 2A in the brain. J Nucl Med. 2016;57(5):777\u201384.","journal-title":"J Nucl Med"},{"issue":"supplement 1","key":"5788_CR41","first-page":"49","volume":"60","author":"S Li","year":"2019","unstructured":"Li S, et al. First-in-human evaluation of <\u2009sup\u2009>\u200918\u2009F-SDM-8, a Novel Radiotracer for PET imaging of synaptic vesicle glycoprotein 2A. J Nucl Med. 2019;60(supplement 1):49\u201349.","journal-title":"J Nucl Med"},{"issue":"4","key":"5788_CR42","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2967\/jnumed.120.249144","volume":"62","author":"M Naganawa","year":"2021","unstructured":"Naganawa M, et al. First-in-human evaluation of (18)F-SynVesT-1, a Radioligand for PET imaging of synaptic vesicle glycoprotein 2A. J Nucl Med. 2021;62(4):561\u20137.","journal-title":"J Nucl Med"},{"issue":"11","key":"5788_CR43","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1177\/0271678X17724947","volume":"38","author":"SJ Finnema","year":"2018","unstructured":"Finnema SJ, et al. Kinetic evaluation and test-retest reproducibility of [(11)C]UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humans. J Cereb Blood Flow Metab. 2018;38(11):2041\u201352.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"5","key":"5788_CR44","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s00259-020-05149-3","volume":"48","author":"S Li","year":"2021","unstructured":"Li S, et al. Assessment of test-retest reproducibility of [(18)F]SynVesT-1, a novel radiotracer for PET imaging of synaptic vesicle glycoprotein 2A. Eur J Nucl Med Mol Imaging. 2021;48(5):1327\u201338.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"5788_CR45","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1177\/0271678X20946198","volume":"41","author":"K Smart","year":"2021","unstructured":"Smart K, et al. Binding of the synaptic vesicle radiotracer [(11)C]UCB-J is unchanged during functional brain activation using a visual stimulation task. J Cereb Blood Flow Metab. 2021;41(5):1067\u201379.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"5788_CR46","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13550-020-00670-w","volume":"10","author":"J Bini","year":"2020","unstructured":"Bini J, et al. Human adult and adolescent biodistribution and dosimetry of the synaptic vesicle glycoprotein 2A radioligand (11)C-UCB-J. EJNMMI Res. 2020;10(1):83.","journal-title":"EJNMMI Res"},{"key":"5788_CR47","doi-asserted-by":"crossref","unstructured":"Becker G et al. The rise of synaptic density PET imaging. Molecules, 2020. 25(10).","DOI":"10.3390\/molecules25102303"},{"issue":"Suppl 1","key":"5788_CR48","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.2967\/jnumed.121.263201","volume":"63","author":"RE Carson","year":"2022","unstructured":"Carson RE, et al. Imaging of synaptic density in neurodegenerative disorders. J Nucl Med. 2022;63(Suppl 1):S60\u20137.","journal-title":"J Nucl Med"},{"key":"5788_CR49","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.mcn.2019.02.001","volume":"97","author":"K Heurling","year":"2019","unstructured":"Heurling K, et al. Synaptic vesicle protein 2A as a potential biomarker in synaptopathies. Mol Cell Neurosci. 2019;97:34\u201342.","journal-title":"Mol Cell Neurosci"},{"key":"5788_CR50","doi-asserted-by":"crossref","unstructured":"Sjoerd J, Finnema SL, Cai Z, Naganawa M, Chen M-K, Matuskey D et al. PET Imaging of Synaptic Vesicle Protein 2A, A.O. Rudi A.J.O. Dierckx, Erik F.J. de Vries, Aren van Waarde, Adriaan A. Lammertsma, Editor. 2021, Springer Cham.","DOI":"10.1007\/978-3-030-53176-8_29"},{"issue":"10","key":"5788_CR51","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1111\/ene.15451","volume":"29","author":"Y Tang","year":"2022","unstructured":"Tang Y, et al. Detection of changes in synaptic density in amyotrophic lateral sclerosis patients using (18) F-SynVesT-1 positron emission tomography. Eur J Neurol. 2022;29(10):2934\u201343.","journal-title":"Eur J Neurol"},{"issue":"1","key":"5788_CR52","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41467-019-14122-0","volume":"11","author":"EC Onwordi","year":"2020","unstructured":"Onwordi EC, et al. Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. Nat Commun. 2020;11(1):246.","journal-title":"Nat Commun"},{"key":"5788_CR53","doi-asserted-by":"crossref","unstructured":"Onwordi EC, et al. Synaptic terminal density early in the course of Schizophrenia: an in vivo UCB-J Positron Emission Tomographic Imaging study of synaptic vesicle glycoprotein 2A. Biol Psychiatry; 2023.","DOI":"10.1016\/j.biopsych.2023.05.022"},{"key":"5788_CR54","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jpsychires.2023.02.026","volume":"161","author":"JH Yoon","year":"2023","unstructured":"Yoon JH, et al. Reductions in synaptic marker SV2A in early-course Schizophrenia. J Psychiatr Res. 2023;161:213\u20137.","journal-title":"J Psychiatr Res"},{"issue":"9","key":"5788_CR55","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1177\/0271678X19879230","volume":"40","author":"S Rossano","year":"2020","unstructured":"Rossano S, et al. Assessment of a white matter reference region for (11)C-UCB-J PET quantification. J Cereb Blood Flow Metab. 2020;40(9):1890\u2013901.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"4","key":"5788_CR56","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.neuroimage.2012.03.072","volume":"61","author":"H Zhang","year":"2012","unstructured":"Zhang H, et al. NODDI: practical in vivo neurite orientation dispersion and density imaging of the human brain. NeuroImage. 2012;61(4):1000\u201316.","journal-title":"NeuroImage"},{"issue":"9","key":"5788_CR57","first-page":"855","volume":"5","author":"A Nazeri","year":"2020","unstructured":"Nazeri A, et al. In Vivo Imaging of Gray Matter Microstructure in Major Psychiatric disorders: opportunities for clinical translation. Biol Psychiatry Cogn Neurosci Neuroimaging. 2020;5(9):855\u201364.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"issue":"9","key":"5788_CR58","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.recesp.2021.06.016","volume":"74","author":"MJ Page","year":"2021","unstructured":"Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed). 2021;74(9):790\u20139.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"4","key":"5788_CR59","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/oxfordjournals.schbul.a007040","volume":"29","author":"TJ Miller","year":"2003","unstructured":"Miller TJ, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2003;29(4):703\u201315.","journal-title":"Schizophr Bull"},{"issue":"4","key":"5788_CR60","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1055\/s-2008-1038155","volume":"76","author":"A Riecher-Rossler","year":"2008","unstructured":"Riecher-Rossler A, et al. [The Basel Screening Instrument for psychosis (BSIP): development, structure, reliability and validity]. Fortschr Neurol Psychiatr. 2008;76(4):207\u201316.","journal-title":"Fortschr Neurol Psychiatr"},{"issue":"4","key":"5788_CR61","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2174\/138161212799316064","volume":"18","author":"F Schultze-Lutter","year":"2012","unstructured":"Schultze-Lutter F, et al. Basic symptoms and the prediction of first-episode psychosis. Curr Pharm Des. 2012;18(4):351\u20137.","journal-title":"Curr Pharm Des"},{"issue":"5","key":"5788_CR62","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000106311","volume":"40","author":"A Vollmer-Larsen","year":"2007","unstructured":"Vollmer-Larsen A, Handest P, Parnas J. Reliability of measuring anomalous experience: the Bonn Scale for the Assessment of Basic symptoms. Psychopathology. 2007;40(5):345\u20138.","journal-title":"Psychopathology"},{"issue":"11\u201312","key":"5788_CR63","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1080\/j.1440-1614.2005.01714.x","volume":"39","author":"AR Yung","year":"2005","unstructured":"Yung AR, et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry. 2005;39(11\u201312):964\u201371.","journal-title":"Aust N Z J Psychiatry"},{"key":"5788_CR64","unstructured":"Healh NIo. Study Quality Assessment Tools. 2021 14 May 2023]; https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools."},{"key":"5788_CR65","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1146\/annurev-bioeng-062117-121056","volume":"21","author":"JM Hooker","year":"2019","unstructured":"Hooker JM, Carson RE. Human Positron Emission Tomography Neuroimaging. Annu Rev Biomed Eng. 2019;21:551\u201381.","journal-title":"Annu Rev Biomed Eng"},{"issue":"3","key":"5788_CR66","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/XEB.0000000000000065","volume":"13","author":"C Tufanaru","year":"2015","unstructured":"Tufanaru C, et al. Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness. Int J Evid Based Healthc. 2015;13(3):196\u2013207.","journal-title":"Int J Evid Based Healthc"},{"issue":"3","key":"5788_CR67","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/schbul\/sbz116","volume":"46","author":"E Alkan","year":"2020","unstructured":"Alkan E, et al. Brain structural correlates of Metacognition in First-Episode Psychosis. Schizophr Bull. 2020;46(3):552\u201361.","journal-title":"Schizophr Bull"},{"key":"5788_CR68","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.schres.2021.01.016","volume":"229","author":"FM Hanlon","year":"2021","unstructured":"Hanlon FM, et al. The clinical relevance of gray matter atrophy and microstructural brain changes across the psychosis continuum. Schizophr Res. 2021;229:12\u201321.","journal-title":"Schizophr Res"},{"issue":"10","key":"5788_CR69","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.biopsych.2016.12.005","volume":"82","author":"A Nazeri","year":"2017","unstructured":"Nazeri A, et al. Gray Matter Neuritic Microstructure Deficits in Schizophrenia and Bipolar Disorder. Biol Psychiatry. 2017;82(10):726\u201336.","journal-title":"Biol Psychiatry"},{"key":"5788_CR70","first-page":"638","volume":"10433","author":"P Parvathaneni","year":"2017","unstructured":"Parvathaneni P, et al. Gray Matter Surface based Spatial Statistics (GS-BSS) in Diffusion Microstructure. Med Image Comput Comput Assist Interv. 2017;10433:638\u201346.","journal-title":"Med Image Comput Comput Assist Interv"},{"issue":"1","key":"5788_CR71","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41398-021-01515-3","volume":"11","author":"EC Onwordi","year":"2021","unstructured":"Onwordi EC, et al. The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study. Transl Psychiatry. 2021;11(1):393.","journal-title":"Transl Psychiatry"},{"issue":"2","key":"5788_CR72","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261\u201376.","journal-title":"Schizophr Bull"},{"issue":"2","key":"5788_CR73","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/arclin\/acp010","volume":"24","author":"P Maruff","year":"2009","unstructured":"Maruff P, et al. Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch Clin Neuropsychol. 2009;24(2):165\u201378.","journal-title":"Arch Clin Neuropsychol"},{"issue":"2","key":"5788_CR74","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1176\/appi.ajp.2007.07010042","volume":"165","author":"KH Nuechterlein","year":"2008","unstructured":"Nuechterlein KH, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165(2):203\u201313.","journal-title":"Am J Psychiatry"},{"key":"5788_CR75","doi-asserted-by":"crossref","unstructured":"Deeks J, Higgins J, Altman D. Chap. 10: Analysing data and undertaking meta-analyses. Cochrane; 2019.","DOI":"10.1002\/9781119536604.ch10"},{"issue":"1","key":"5788_CR76","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.schres.2008.08.014","volume":"107","author":"VC Leeson","year":"2009","unstructured":"Leeson VC, et al. IQ as a predictor of functional outcome in schizophrenia: a longitudinal, four-year study of first-episode psychosis. Schizophr Res. 2009;107(1):55\u201360.","journal-title":"Schizophr Res"},{"key":"5788_CR77","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.pharmthera.2015.06.008","volume":"153","author":"EM Tsapakis","year":"2015","unstructured":"Tsapakis EM, Dimopoulou T, Tarazi FI. Clinical management of negative symptoms of schizophrenia: an update. Pharmacol Ther. 2015;153:135\u201347.","journal-title":"Pharmacol Ther"},{"key":"5788_CR78","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.molimm.2019.07.030","volume":"114","author":"WM Zelek","year":"2019","unstructured":"Zelek WM, et al. Compendium of current complement therapeutics. Mol Immunol. 2019;114:341\u201352.","journal-title":"Mol Immunol"},{"issue":"8","key":"5788_CR79","doi-asserted-by":"publisher","first-page":"e0182340","DOI":"10.1371\/journal.pone.0182340","volume":"12","author":"A Mah","year":"2017","unstructured":"Mah A, Geeraert B, Lebel C. Detailing neuroanatomical development in late childhood and early adolescence using NODDI. PLoS ONE. 2017;12(8):e0182340.","journal-title":"PLoS ONE"},{"issue":"1","key":"5788_CR80","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.bpsgos.2021.12.012","volume":"3","author":"NV Kraguljac","year":"2023","unstructured":"Kraguljac NV, et al. Neurite Orientation Dispersion and Density Imaging in Psychiatric disorders: a Systematic Literature Review and a technical note. Biol Psychiatry Glob Open Sci. 2023;3(1):10\u201321.","journal-title":"Biol Psychiatry Glob Open Sci"},{"key":"5788_CR81","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.neurobiolaging.2021.01.016","volume":"101","author":"E Mak","year":"2021","unstructured":"Mak E, et al. In vivo coupling of dendritic complexity with presynaptic density in primary tauopathies. Neurobiol Aging. 2021;101:187\u201398.","journal-title":"Neurobiol Aging"},{"issue":"3","key":"5788_CR82","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.pneurobio.2011.08.003","volume":"95","author":"MR Bennett","year":"2011","unstructured":"Bennett MR. Schizophrenia: susceptibility genes, dendritic-spine pathology and gray matter loss. Prog Neurobiol. 2011;95(3):275\u2013300.","journal-title":"Prog Neurobiol"},{"issue":"1","key":"5788_CR83","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41386-022-01370-w","volume":"48","author":"LG Appelbaum","year":"2023","unstructured":"Appelbaum LG, et al. Synaptic plasticity and mental health: methods, challenges and opportunities. Neuropsychopharmacology. 2023;48(1):113\u201320.","journal-title":"Neuropsychopharmacology"},{"key":"5788_CR84","doi-asserted-by":"publisher","first-page":"113741","DOI":"10.1016\/j.expneurol.2021.113741","volume":"342","author":"KH Binda","year":"2021","unstructured":"Binda KH, et al. Exercise protects synaptic density in a rat model of Parkinson\u2019s disease. Exp Neurol. 2021;342:113741.","journal-title":"Exp Neurol"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-024-05788-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-024-05788-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-024-05788-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T01:02:37Z","timestamp":1718845357000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-024-05788-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,19]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5788"],"URL":"https:\/\/doi.org\/10.1186\/s12888-024-05788-y","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,19]]},"assertion":[{"value":"24 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"MOH receives funding from the Canadian Institutes of Health Research (CIHR), the University of Toronto and Slaight Family Centre for Youth in Transition. MIH was previously Trustees of the Pakistan Institute of Learning and Living and is a PI for a trial sponsored by COMPASS Pathways Limited. All other authors do not have any competing interests related to this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"460"}}